EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Frequency and Implications of High‐Risk Pharmacogenomic Phenotypes Identified in a Diverse Australian Pediatric Oncology Cohort

Claire Moore iD, Andreas Halman iD, Tayla Stenta iD, Dhrita Khatri iD, Elizabeth Williams iD, Roxanne Dyas iD, Julian Stolper iD, David A Elliott iD, Rachel Conyers iD

Clinical and Translational Science · 2025

DOI: 10.1111/cts.70246 ↗

At a glance

Journal article in Clinical and Translational Science, 2025. Written by Claire Moore and 8 co-authors. Institution: Cancer Therapies, Stem Cell Medicine, Murdoch Children's Research Institute, Parkville, Victoria, Australia. Major MEDLINE topics: Neoplasms, Pharmacogenomic Testing, Pharmacogenetics, Drug-Related Side Effects and Adverse Reactions. Cited 7 times so far (Crossref); 49 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Melbourne University Strategic Research Training Program (RTP) Scholarship, The Kids' Cancer Project, The Royal Children's Hospital Foundation.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Pharmacogenomics remains underutilized in pediatric oncology, despite the existence of evidence‐based guidelines. Implementation of pharmacogenomics‐informed prescribing could improve medication safety and efficacy in pediatric oncology patients, who are at high risk of adverse drug reactions. This study examines the prevalence of high‐risk pharmacogenomic phenotypes and the prescription of relevant medications in a diverse Australian pediatric oncology cohort, highlighting the potential impact of pharmacogenomic testing in this unique population. Whole genome sequencing data from 180 patients were analyzed to assess 14 genes with evidence‐based pharmacogenomic guidelines relevant to pediatric oncology. Over 90% of patients had at least one high‐risk phenotype, with 20% presenting four or more. Ondansetron, mercaptopurine, omeprazole, pantoprazole, and voriconazole were commonly prescribed medications that have pharmacogenomic prescribing recommendations, with the latter three showing the highest actionability rates. High‐risk phenotypes were most frequently observed for CYP2C19 and CYP2D6 , with 30% of patients having a high‐risk phenotype for both genes. This study underscores the potential utility of pharmacogenomics in pediatric oncology patients across a range of pharmacogenes and commonly prescribed medications. The findings support advocacy for implementing broad, pre‐emptive pharmacogenomic testing in oncology patients to improve treatment safety and efficacy.

Subjects

MeSH terms (MEDLINE)

NeoplasmsPharmacogenomic TestingPharmacogeneticsDrug-Related Side Effects and Adverse ReactionsAntineoplastic AgentsHumansChildAustraliaMalePhenotypeFemaleChild, PreschoolAdolescentInfantCytochrome P-450 CYP2C19Whole Genome SequencingCohort StudiesCytochrome P-450 CYP2D6

Author keywords

medical oncologypediatricspharmacogeneticspharmacogenomicsprecision medicine

Substances

Cytochrome P-450 CYP2C19CYP2C19 protein, humanCytochrome P-450 CYP2D6Antineoplastic Agents

Authors and institutions

  • Cancer Therapies, Stem Cell Medicine, Murdoch Children's Research Institute, Parkville, Victoria, Australia.
  • Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia.
  • Children's Cancer Centre, The Royal Children's Hospital, Parkville, Victoria, Australia.
  • Victorian Clinical Genetics Services, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
  • The Novo Nordisk Foundation Centre for Stem Cell Medicine, ReNEW, Melbourne Node, Parkville, Victoria, Australia.
  • Australian Regenerative Medicine Institute, Monash University, Clayton, Victoria, Australia.

ORCID profiles: Claire Moore, Andreas Halman, Tayla Stenta, Dhrita Khatri, Elizabeth Williams, Roxanne Dyas, Julian Stolper, David A Elliott, Rachel Conyers

Funding

  • Melbourne University Strategic Research Training Program (RTP) Scholarship
  • The Kids' Cancer Project
  • The Royal Children's Hospital Foundation
  • 2020 Medical Research Future Fund - Emerging Priorities and Consumer Driven Research Initiative - Paediatric Cancer
  • 2023 Medical Research Future Fund - Genomics Health Future Mission
  • Royal Children's Hospital Foundation

Cite

APA

Moore, C., Halman, A., Stenta, T., Khatri, D., Williams, E., Dyas, R., Stolper, J., Elliott, D. A., & Conyers, R. (2025). Frequency and Implications of High‐Risk Pharmacogenomic Phenotypes Identified in a Diverse Australian Pediatric Oncology Cohort. Clinical and Translational Science. https://doi.org/10.1111/cts.70246

Vancouver

Moore C, Halman A, Stenta T, Khatri D, Williams E, Dyas R, et al. Frequency and Implications of High‐Risk Pharmacogenomic Phenotypes Identified in a Diverse Australian Pediatric Oncology Cohort. Clinical and Translational Science. 2025. doi:10.1111/cts.70246

BibTeX
@article{Moore2025,
  author = {Moore, Claire and Halman, Andreas and Stenta, Tayla and Khatri, Dhrita and Williams, Elizabeth and Dyas, Roxanne and Stolper, Julian and Elliott, David A and Conyers, Rachel},
  title = {Frequency and Implications of High‐Risk Pharmacogenomic Phenotypes Identified in a Diverse Australian Pediatric Oncology Cohort},
  journal = {Clinical and Translational Science},
  year = {2025},
  doi = {10.1111/cts.70246}
}
Start for free →